- Home
- RCUS vs DEA Comparison
RCUS vs DEA Comparison
Compare RCUS & DEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCUS
- DEA
- Stock Information
- Founded
- RCUS 2015
- DEA 2011
- Country
- RCUS United States
- DEA United States
- Employees
- RCUS N/A
- DEA N/A
- Industry
- RCUS Biotechnology: Pharmaceutical Preparations
- DEA Real Estate Investment Trusts
- Sector
- RCUS Health Care
- DEA Real Estate
- Exchange
- RCUS Nasdaq
- DEA Nasdaq
- Market Cap
- RCUS 1.2B
- DEA 1.1B
- IPO Year
- RCUS 2018
- DEA 2015
- Fundamental
- Price
- RCUS $11.07
- DEA $10.79
- Analyst Decision
- RCUS Buy
- DEA Buy
- Analyst Count
- RCUS 11
- DEA 2
- Target Price
- RCUS $31.11
- DEA $12.50
- AVG Volume (30 Days)
- RCUS 1.1M
- DEA 1.3M
- Earning Date
- RCUS 02-25-2025
- DEA 02-25-2025
- Dividend Yield
- RCUS N/A
- DEA 9.90%
- EPS Growth
- RCUS N/A
- DEA N/A
- EPS
- RCUS N/A
- DEA 0.17
- Revenue
- RCUS $263,000,000.00
- DEA $302,121,000.00
- Revenue This Year
- RCUS $127.65
- DEA N/A
- Revenue Next Year
- RCUS N/A
- DEA $8.91
- P/E Ratio
- RCUS N/A
- DEA $62.68
- Revenue Growth
- RCUS 119.17
- DEA 2.98
- 52 Week Low
- RCUS $10.63
- DEA $10.45
- 52 Week High
- RCUS $20.31
- DEA $14.53
- Technical
- Relative Strength Index (RSI)
- RCUS 34.34
- DEA 43.14
- Support Level
- RCUS $10.63
- DEA $10.45
- Resistance Level
- RCUS $13.49
- DEA $10.87
- Average True Range (ATR)
- RCUS 0.77
- DEA 0.22
- MACD
- RCUS -0.13
- DEA -0.00
- Stochastic Oscillator
- RCUS 13.88
- DEA 44.67
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
About DEA Easterly Government Properties Inc.
Easterly Government Properties Inc is a real estate investment trust. It is engaged in the acquisition, development, and management of Class A commercial properties that are leased to U.S. government agencies. The company generates all its revenue by leasing its properties to such agencies.